Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis Reports Second Quarter 2021 Financial Results
04:00pm, Tuesday, 03'rd Aug 2021
LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported it
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 07'th Jul 2021
LEXINGTON, Mass., July 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
05:50pm, Saturday, 26'th Jun 2021
New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised
Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes
08:00am, Friday, 25'th Jun 2021
LEXINGTON, Mass., June 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
06:35pm, Tuesday, 22'nd Jun 2021
NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to conta
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
04:50am, Wednesday, 16'th Jun 2021
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to conta
Curis' Plunge Is A Buying Opportunity
04:03pm, Sunday, 13'th Jun 2021
CRIS sold off precipitously on toxicity worries for its AML/MDS candidate therapy CA-4948. My reading of the data, however, suggests that the concern is not applicable to the dosage actually selected
Why Curis Fell Off a Cliff on Friday
05:54pm, Friday, 11'th Jun 2021
The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial.
Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial
09:56am, Friday, 11'th Jun 2021
Curis Inc (NASDAQ: CRIS) has announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findi
LEXINGTON, Mass., June 11, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced u
Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA
08:00am, Friday, 04'th Jun 2021
LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th
Curis to Present at Jefferies Virtual Healthcare Conference
08:01am, Tuesday, 25'th May 2021
LEXINGTON, Mass., May 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th
New Strong Sell Stocks for May 20th
09:46am, Thursday, 20'th May 2021
AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
Why Curis Stock Crashed on Thursday
06:42pm, Thursday, 13'th May 2021
The swoon came shortly after some very good news for the company.
Curis (CRIS) Stock: $24 Target By Cantor Fitzgerald
12:31pm, Thursday, 13'th May 2021
The shares of Curis, Inc. (NASDAQ: CRIS) have received a price target increase from $15 to $24 by Cantor Fitzgerald. These are the details.
